Page 13 - Prostate cancer in Europe: the time to act is now
Professor Hendrik Van Poppel, a member of the expert group for the Let’s Talk Prostate Cancer (LTPC) initiative, tells Pharmafocus about its new campaign, exploring risk factors, new screening measures and what European Governments should be doing to improve the state of prostate cancer care
- COVID-19 antiviral treatment shown to speed up recovery in trial
– AstraZeneca shares two new drug approvals in the EU
– Tamiflu manufacturers report shortages during peak flu season
– Cost of over 350 drugs expected to increase in 2023
- AI model predicts CVD risk from single chest radiograph
– PMGroup Worldwide Ltd
Group Managing Editor
Design & Layout
is published by:
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2022 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.